Astec LifeSciences (ASTEC) | Financial Analysis & Statements
Astec LifeSciences Ltd. Small-cap Basic Materials
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
910.8M
Gross Profit
272.0M
29.86%
Operating Income
-224.8M
-24.68%
Net Income
-330.3M
-36.26%
EPS (Diluted)
₹-16.72
Balance Sheet Metrics
Total Assets
8.8B
Total Liabilities
6.5B
Shareholders Equity
2.4B
Debt to Equity
2.75
Cash Flow Metrics
Revenue & Profitability Trend
Quarter Income Flow
Jun 30, 2025
Annual Income Flow
2025
Astec LifeSciences Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 3.8B | 4.6B | 6.3B | 6.8B | 5.5B |
| Cost of Goods Sold | 3.0B | 3.2B | 4.1B | 3.9B | 3.5B |
| Gross Profit | 785.9M | 1.3B | 2.2B | 2.9B | 2.1B |
| Gross Margin % | 20.6% | 29.4% | 35.5% | 42.2% | 37.8% |
| Operating Expenses | |||||
| Research & Development | 21.4M | 27.0M | 14.9M | 9.1M | 9.2M |
| Selling, General & Administrative | 123.7M | 97.6M | 197.7M | 189.8M | 129.0M |
| Other Operating Expenses | 677.9M | 649.1M | 709.9M | 598.4M | 447.3M |
| Total Operating Expenses | 823.0M | 773.7M | 922.4M | 797.3M | 585.6M |
| Operating Income | -1.1B | -415.9M | 435.3M | 1.2B | 897.1M |
| Operating Margin % | -28.8% | -9.1% | 6.9% | 17.8% | 16.2% |
| Non-Operating Items | |||||
| Interest Income | 8.0M | 1.5M | 40.5M | 2.6M | 7.8M |
| Interest Expense | 362.8M | 248.6M | 201.6M | 86.9M | 47.5M |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | -1.4B | -617.5M | 349.5M | 1.2B | 890.7M |
| Income Tax | -62.8M | -148.6M | 93.5M | 312.4M | 240.0M |
| Effective Tax Rate % | 0.0% | 0.0% | 26.8% | 25.8% | 26.9% |
| Net Income | -1.3B | -468.9M | 255.9M | 898.8M | 650.7M |
| Net Margin % | -35.3% | -10.2% | 4.1% | 13.3% | 11.7% |
| Key Metrics | |||||
| EBITDA | -636.4M | -5.3M | 891.6M | 1.6B | 1.2B |
| EPS (Basic) | ₹-68.19 | ₹-23.93 | ₹13.04 | ₹45.87 | ₹33.23 |
| EPS (Diluted) | ₹-68.19 | ₹-23.93 | ₹13.04 | ₹45.85 | ₹33.21 |
| Basic Shares Outstanding | 19760921 | 19607450 | 19603024 | 19589899 | 19575811 |
| Diluted Shares Outstanding | 19760921 | 19607450 | 19603024 | 19589899 | 19575811 |
Income Statement Trend
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Astec LifeSciences Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 5.8M | 4.7M | 4.7M | 5.5M | 3.4M |
| Short-term Investments | 2.8M | 11.8M | 2.5M | 27.9M | 12.0M |
| Accounts Receivable | 1.5B | 1.7B | 1.5B | 2.7B | 1.9B |
| Inventory | 1.6B | 2.0B | 2.9B | 1.9B | 1.1B |
| Other Current Assets | 2.0K | 6.0K | 2.0K | 2.0K | 113.0K |
| Total Current Assets | 3.4B | 4.0B | 5.0B | 5.2B | 3.3B |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 317.4M | 245.4M | 172.6M | 169.6M | 54.3M |
| Goodwill | 234.5M | 194.2M | 159.0M | 113.9M | 51.6M |
| Intangible Assets | 234.5M | 194.2M | 159.0M | 113.9M | 51.6M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 105.2M | -1.0K | -2.0K | 129.8M | 1.0K |
| Total Non-Current Assets | 5.4B | 5.8B | 4.8B | 3.8B | 3.5B |
| Total Assets | 8.8B | 9.7B | 9.8B | 9.0B | 6.8B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 816.1M | 892.8M | 1.8B | 1.9B | 1.3B |
| Short-term Debt | 2.7B | 2.9B | 3.3B | 2.8B | 1.5B |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 18.0K | 11.0K | 77.0K | 41.0K | 69.0K |
| Total Current Liabilities | 3.7B | 4.0B | 5.3B | 4.9B | 3.2B |
| Non-Current Liabilities | |||||
| Long-term Debt | 2.8B | 2.0B | 108.6M | 0 | 400.0M |
| Deferred Tax Liabilities | 380.0K | 67.6M | 209.7M | 80.8M | 54.7M |
| Other Non-Current Liabilities | - | - | 13.5M | - | - |
| Total Non-Current Liabilities | 2.8B | 2.1B | 336.6M | 95.1M | 459.9M |
| Total Liabilities | 6.5B | 6.1B | 5.6B | 5.0B | 3.7B |
| Equity | |||||
| Common Stock | 196.1M | 196.1M | 196.1M | 196.0M | 195.9M |
| Retained Earnings | 1.4B | 2.8B | 3.3B | 3.0B | 2.2B |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 2.4B | 3.7B | 4.2B | 4.0B | 3.1B |
| Key Metrics | |||||
| Total Debt | 5.5B | 4.9B | 3.4B | 2.8B | 1.9B |
| Working Capital | -245.7M | 13.3M | -273.5M | 250.9M | 81.5M |
Balance Sheet Composition
Astec LifeSciences Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -1.4B | -617.5M | 349.5M | 1.2B | 890.7M |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | 345.0K | 3.0M | 3.3M | 1.0M | 99.0K |
| Working Capital Changes | 345.1M | 994.9M | 83.1M | -1.7B | -366.8M |
| Operating Cash Flow | -705.5M | 631.1M | 602.5M | -427.8M | 563.7M |
| Investing Activities | |||||
| Capital Expenditures | -158.5M | -1.4B | -1.2B | -1.0B | -1.0B |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | - | -2.8M | -1.1M | - | -324.0K |
| Investment Sales | - | - | - | - | - |
| Investing Cash Flow | -158.5M | -1.4B | -1.2B | -1.0B | -736.9M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | -29.4M | -29.4M | -29.4M | -29.4M |
| Debt Issuance | 1.5B | 2.0B | 1.4B | 0 | 883.5M |
| Debt Repayment | -607.6M | -439.6M | -1.3B | 0 | - |
| Financing Cash Flow | 622.9M | 2.0B | 578.4M | 893.9M | 1.3B |
| Free Cash Flow | -302.2M | -1.3B | -426.0M | -803.7M | -1.1B |
| Net Change in Cash | -241.2M | 1.3B | 13.8M | -572.5M | 1.2B |
Cash Flow Trend
Astec LifeSciences Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
399.52
Forward P/E
47.17
Price to Book
3.85
Price to Sales
4.03
PEG Ratio
-6.22
Profitability Ratios
Profit Margin
-21.82%
Operating Margin
-5.80%
Return on Equity
-57.34%
Return on Assets
-15.29%
Financial Health
Current Ratio
0.93
Debt to Equity
88.61
Beta
-0.14
Per Share Data
EPS (TTM)
₹-42.30
Book Value per Share
₹192.33
Revenue per Share
₹197.16
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| ASTEC | 16.4B | 399.52 | 3.85 | -57.34% | -21.82% | 88.61 |
| UPL | 620.3B | 3.00 | 1.63 | 2.01% | 0.09% | 105.06 |
| Coromandel | 588.1B | 24.57 | 4.83 | 18.41% | 7.87% | 11.60 |
| Kaveri Seed Company | 48.3B | 16.04 | 2.69 | 18.71% | 21.82% | 0.00 |
| Dhanuka Agritech | 45.5B | 6.46 | 2.95 | 21.17% | 13.39% | 2.06 |
| Madhya Bharat Agro | 44.4B | 42.34 | 9.68 | 14.23% | 5.92% | 68.15 |
Financial data is updated regularly. All figures are in the company's reporting currency.




